Scholarlink

<p>In 2023, approximately 7.41% of women in Germany had gestational diabetes mellitus (GDM); 1.14% of pregnant women had pre-existing diabetes mellitus. Automated insulin dosing (AID) systems improve blood glucose control in both nonpregnant adults and children. The AiDAPT study with the CamAPS FX algorithm showed that glycemic control can be significantly improved during pregnancy, meaning that tight regulation within the pregnancy-specific target range (3.5–7.8 mmol/l; 63–140 mg/dl) is better achieved, women’s quality of life is enhanced, and the AID system is safe. The Medtronic MiniMed 780G system also achieved better nocturnal blood glucose levels and reduced hypoglycemia in the CRISTAL study. Overall, these data indicate that AID systems are safe and effective during pregnancy, with only CamAPS FX being CE-certified for use in pregnancy. In type&#xa0;2 diabetes mellitus (T2DM) and obesity, the use of incretin mimetics is increasing, even among young obese women with and without T2DM in reproductive age. Additionally, weight reduction often leads to improved insulin resistance, which can enhance fertility, potentially leading to unplanned conception. Current database analyses show no increased risk of birth defects; however, incretin mimetics should be discontinued when planning or upon pregnancy confirmation, and reliable contraception should be used. Early diagnosis and treatment of GDM, especially in early pregnancy, can reduce complications, although the optimal testing method in early pregnancy is still unclear. Continuous glucose monitoring (CGM) could already provide indications of GDM before diagnosis. Recent data from Germany suggest that postpartum screening for T2DM after GDM may be risk-adapted to avoid unnecessary tests.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Schwangerschaft und Diabetes – ein Update

  • 期刊论文

  • 发表日期：

    2025年6月24日

查看全文
  • Katharina Laubner

摘要

In 2023, approximately 7.41% of women in Germany had gestational diabetes mellitus (GDM); 1.14% of pregnant women had pre-existing diabetes mellitus. Automated insulin dosing (AID) systems improve blood glucose control in both nonpregnant adults and children. The AiDAPT study with the CamAPS FX algorithm showed that glycemic control can be significantly improved during pregnancy, meaning that tight regulation within the pregnancy-specific target range (3.5–7.8 mmol/l; 63–140 mg/dl) is better achieved, women’s quality of life is enhanced, and the AID system is safe. The Medtronic MiniMed 780G system also achieved better nocturnal blood glucose levels and reduced hypoglycemia in the CRISTAL study. Overall, these data indicate that AID systems are safe and effective during pregnancy, with only CamAPS FX being CE-certified for use in pregnancy. In type 2 diabetes mellitus (T2DM) and obesity, the use of incretin mimetics is increasing, even among young obese women with and without T2DM in reproductive age. Additionally, weight reduction often leads to improved insulin resistance, which can enhance fertility, potentially leading to unplanned conception. Current database analyses show no increased risk of birth defects; however, incretin mimetics should be discontinued when planning or upon pregnancy confirmation, and reliable contraception should be used. Early diagnosis and treatment of GDM, especially in early pregnancy, can reduce complications, although the optimal testing method in early pregnancy is still unclear. Continuous glucose monitoring (CGM) could already provide indications of GDM before diagnosis. Recent data from Germany suggest that postpartum screening for T2DM after GDM may be risk-adapted to avoid unnecessary tests.